This company has been marked as potentially delisted and may not be actively trading. Sinovac Biotech (SVA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendFDA EventsHeadlinesOptions ChainOwnershipTrendsBuy This Stock SVA vs. KNSA, LQDA, TARS, FOLD, IBRX, DNLI, AGIO, GLPG, IDYA, and HRMYShould you be buying Sinovac Biotech stock or one of its competitors? The main competitors of Sinovac Biotech include Kiniksa Pharmaceuticals International (KNSA), Liquidia Technologies (LQDA), Tarsus Pharmaceuticals (TARS), Amicus Therapeutics (FOLD), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), IDEAYA Biosciences (IDYA), and Harmony Biosciences (HRMY). These companies are all part of the "med - biomed/gene" industry. Sinovac Biotech vs. Its Competitors Kiniksa Pharmaceuticals International Liquidia Technologies Tarsus Pharmaceuticals Amicus Therapeutics ImmunityBio Denali Therapeutics Agios Pharmaceuticals Galapagos IDEAYA Biosciences Harmony Biosciences Sinovac Biotech (NASDAQ:SVA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Does the media refer more to SVA or KNSA? In the previous week, Kiniksa Pharmaceuticals International had 12 more articles in the media than Sinovac Biotech. MarketBeat recorded 12 mentions for Kiniksa Pharmaceuticals International and 0 mentions for Sinovac Biotech. Kiniksa Pharmaceuticals International's average media sentiment score of 0.50 beat Sinovac Biotech's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Overall Sentiment Sinovac Biotech Neutral Kiniksa Pharmaceuticals International Positive Is SVA or KNSA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Sinovac Biotech's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Sinovac Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Sinovac BiotechN/A N/A N/A Kiniksa Pharmaceuticals International 0.90%1.05%0.80% Which has higher valuation and earnings, SVA or KNSA? Kiniksa Pharmaceuticals International has lower revenue, but higher earnings than Sinovac Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSinovac Biotech$448.27M1.44-$99.92MN/AN/AKiniksa Pharmaceuticals International$423.24M5.87-$43.19M$0.04837.48 Do insiders and institutionals hold more shares of SVA or KNSA? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend SVA or KNSA? Kiniksa Pharmaceuticals International has a consensus target price of $41.17, suggesting a potential upside of 22.89%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Sinovac Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, SVA or KNSA? Sinovac Biotech has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. SummaryKiniksa Pharmaceuticals International beats Sinovac Biotech on 12 of the 14 factors compared between the two stocks. Get Sinovac Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVA vs. The Competition Export to ExcelMetricSinovac BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$644.67M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E RatioN/A20.4630.4325.11Price / Sales1.44237.31392.2187.48Price / Cash38.9542.3737.0358.50Price / Book0.057.959.016.20Net Income-$99.92M-$54.72M$3.26B$265.38M Sinovac Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVASinovac BiotechN/A$6.47flatN/AN/A$644.67M$448.27M0.003,261High Trading VolumeKNSAKiniksa Pharmaceuticals International2.4271 of 5 stars$33.46-0.8%$41.17+23.0%+26.1%$2.48B$423.24M835.33220Insider TradeLQDALiquidia Technologies3.5175 of 5 stars$27.42-1.1%$32.11+17.1%+184.9%$2.36B$14M-16.1550TARSTarsus Pharmaceuticals1.8382 of 5 stars$54.52-0.2%$66.67+22.3%+111.2%$2.30B$182.95M-23.3850FOLDAmicus Therapeutics4.3118 of 5 stars$7.35-0.9%$16.22+120.9%-37.9%$2.26B$528.29M-61.20480News CoveragePositive NewsIBRXImmunityBio2.2937 of 5 stars$2.33-4.3%$10.75+362.4%-43.1%$2.20B$14.74M-4.84590DNLIDenali Therapeutics4.1405 of 5 stars$14.76-0.4%$33.62+127.7%-38.6%$2.16BN/A-5.28430News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAGIOAgios Pharmaceuticals4.2941 of 5 stars$36.95-1.3%$56.33+52.5%-17.9%$2.15B$36.50M3.36390GLPGGalapagos0.3485 of 5 stars$32.30-1.9%$25.33-21.6%+27.9%$2.13B$275.61M0.001,310Positive NewsIDYAIDEAYA Biosciences4.4787 of 5 stars$24.00-3.0%$48.09+100.4%-38.5%$2.10B$7M-6.3380HRMYHarmony Biosciences4.5463 of 5 stars$36.33-0.2%$51.00+40.4%+2.3%$2.09B$714.73M11.72200News Coverage Related Companies and Tools Related Companies KNSA Alternatives LQDA Alternatives TARS Alternatives FOLD Alternatives IBRX Alternatives DNLI Alternatives AGIO Alternatives GLPG Alternatives IDYA Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sinovac Biotech, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sinovac Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access